MATWIN 2012NOT CONFIDENTIAL Letter of Intent

NOT CONFIDENTIAL

1Summary

Research project title

/ Name of the Cancerôpole partner
Please type your title here

Project acronym

/ For official use only
Please indicate your project acronym here.

Key words

/ Dossier no :
Please type specific key words that you think best describe and categorize your proposed research.

Applicant’s full name (project leader)

Title[1]
First Name
Last Name
Function[2]
Team number
Department/laboratory
University / Faculty / School
Host Institution[3]
CONTACT DETAILS
Address
E-mail
Tel(direct line) / mobile / +33 / +33 6
Fax (if available)
Technology Transfer Office

Requested budget & total duration of the project

Matwin requested budget: / (K€, ATI) / Total duration of project: / months

2Letter of Intent

Abstract (400 words max) Title, Application domain, objective, expected outcomes

Résumé (500 mots max) –Titre, Domaine d’application, objectif, résultats attendus

Associated teams/partners (scientific and non–scientific)[4]

Team number / Team leader’s name / Department / Laboratory / Faculty /
School / Leader’s function / Leader’s expertise (in general, relevant for the project)
1
2
3
4
5

Breakdown of requested budget and other funding sources

Staff costs
Running expenses (reagent, consumables…)
Subcontracting internal external (% it represents of the total budget)[5]
Equipment costs
Other funding sources (ANR, INCa,FP7…) / Amount in K€, ATI / Obtained / Expected
(please specify when)
 /  / date
 / 
 / 
 / 

International Project Classification[6]

Which of the following NCI-TRWG6 Developmental Pathway(s) best applies to your Project? Please place an “X” at the corresponding box:

A– Assessment Modalities: Intended to characterize the cancer-related health status of an individual
1. Biospecimen-based assessment devices (protocols, reagents, instruments)
2. Image-based assessment (agents or techniques)
B- Interventive Modalities: Intended to change the cancer-related health status of an individual, via prevention or treatment
1. Immune response modifiers (vaccines, cytokines, cellular therapy, etc)
2. Interventive devices (surgery, radiation)
3. Lifestyle alterations (diet, behavioural mechanisms, etc)
4. Agents (drugs or biologics including stem cells, epigenetic targets, gene expression)

Project descriptionand expected outcomes (4 pages max.)

You are requested to present your project research plan from an industrial perspective. Your presentation should not exceed 4 pages and should be structured as follow:

  1. Scientific background (state of the art),rationale and supporting references of relevance to this project
  2. Innovative components and description of unmet medical needs: relevance to cancer, potential applications (prognosis, diagnosis, treatment…)
  3. End products/devices: please briefly describe what product/device will be delivered to patients and healthcare professionals, if possible the anticipated benefits for patients and healthcare professionalsand its competitive positioning
  4. Project Main Objective:
  5. Work plan: please list the key steps to reach the objective and for each step briefly describe the experimental design and main deliverables (do not forget this present letter is not confidential)

SWOT analysis of the project

A SWOT analysis is a strategic planning method used to evaluate the Strengths, Weaknesses, Opportunities, and Threats involved in a project. It involves specifying the Objective of the project and identifying the key internal (S,W) and external (O, T) factors that are favourable and unfavourable to achieving that objective. External factors can be existing or upcoming competitors, regulatory or ethical issues, technology acceptance by professionals/patients…

Strengths / Weaknesses
Opportunities / Threats

Intellectual property: Patents, Commercial Interests

Please complete a table for each patent you already filed or that you are planning to file:

Patent n°1
Invention title:
Field of application:
IP status:
(N.B.: only projects whose patent are filed by December are eligible to participate in Matwin)
Please place an “X” in the appropriate box. /
  1. Invention disclosure:
  2. Date of disclosure: ……………………….
  3. Expected date for filling: ………………………..

  1. Patent filing: Date: ………………………..

  1. Patent Cooperation Treaty (PCT): PCT number: WO……………….

  1. Awarded patent
  2. Patent number:…………………
  3. Awarded countries:……………..

Inventor(s):
Patent co-owners (institutions):

Main publications of associated partners (limited to 5 publications for each partner and with scientific and technical relevance to this project, please include electronic link to medline/pubmed if possible). Indicate previously submitted patents if any

List of academic and industrial experts

Proposed experts in the field without conflict of interest:

  1. Xx
.....

Undesirable experts because of conflict of interest:

  1. Xx
.....

Applicant Signature

I, undertaking ………………………………………………………[name]
  1. authorise my Cancéropôle and the society MATWIN to share all information regarding my Letter of Intent for evaluation purposes, under the condition that each person who accesses this information is bound by a confidentiality agreement
  2. have obtained the agreement of all associated partners for their participation in this research project.
  3. am aware the present letter of intent will be disclosed to third partiers and therefore does not contain confidential information.
Date: Signature:

Appendix 1: Contact details

The Letter of intent must be returned at the latest beforeApril 30th 2012 to:

1)MATWIN Platform / By e-mail in pdf format to:
AND
2)Your Cancerôpole / By e-mail the pdf format and by mail the original copy to the following address
/ Cancerôpole CLARA – Programme MATWIN
60 avenue Rockefeller 69008 Lyon
 - : 04 37 90 17 15
/ Cancerôpole GO – Programme MATWIN
Maison de la Recherche en Santé, 5, Allée de l’Ile Gloriette 44093 NANTES cedex 01
 - : 02 53 48 28 75
/ Cancerôpole GSO – Programme MATWIN
Hôpital La Grave, Place Lange - TSA 60033 – 31059 TOULOUSE cedex 9
 - : 05 82 95 13 94
/ Cancerôpole NO – Programme MATWIN
1 Avenue Oscar Lambret - B.P. 90005 - 59008 Lille Cedex – France
 - : 03 20 74 35 83
/ Cancerôpole PACA – Programme MATWIN
Faculté de Médecine-Timone, 27 boulevard Jean Moulin, 13005 Marseille
 - : 04 91 32 47 02
Others Cancerôpoles or institutions / Cécile FAURIE - MATWIN SAS
Institut Bergonié – 229 cours de l’Argonne – 33076 Bordeaux cedex, France
: 06 84 01 61 70

Appendix 1:MATWIN timetable

Call for projects / 2012 March 01st
Expression of interest - Deadline “Letter of Intent“ / 2012 April 30th
Notification of acceptance for “Letter of Intent” / From 2012 May 15th
Deadline for submission of “Project Application Form” / 2012 August 30th
Multidisciplinary analysis of projects / 2012 September to December
Letter to selected or unselected applicants / From 2012 December 15th
Review of research plan and training for the final presentation / 2013 January to April
Project Presentation to the MATWIN International Board / 2013 May
Board projects recommendation / 2013 May

Not Confidential – Fev 2012Page 1 on 7

[1]Examples: PhD, engineer, professor, medical doctor, PhD Student, Other

[2] Examples: team leader, lab head, research director, senior scientist, clinician…

[3]Examples: CNRS, INSERM, CEA. University, CHU, other (precise)

[4] Our recommendation is to limit number of associated partners to 3 to 5 teams, including yours.

[5] This amount cannot be more than 30% of the Matwin requested budget without Matwin authorisation

[6] Based on the National Cancer Institute (USA) Classification established by the Translational Research Working Group